US20010006989A1 - Method for preparing malonate methylidene nanoparticles, nanoparticles optionally containing one or several biologically active molecules - Google Patents
Method for preparing malonate methylidene nanoparticles, nanoparticles optionally containing one or several biologically active molecules Download PDFInfo
- Publication number
- US20010006989A1 US20010006989A1 US09/770,303 US77030301A US2001006989A1 US 20010006989 A1 US20010006989 A1 US 20010006989A1 US 77030301 A US77030301 A US 77030301A US 2001006989 A1 US2001006989 A1 US 2001006989A1
- Authority
- US
- United States
- Prior art keywords
- nanoparticles
- compound
- formula
- group
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C(=C)C(=O)OC.COC(=O)COC(C)=O.COC(C)=O Chemical compound *C(=C)C(=O)OC.COC(=O)COC(C)=O.COC(C)=O 0.000 description 11
- GOQRKXBLBLOWLQ-UHFFFAOYSA-N COC(=O)COC(C)=O Chemical compound COC(=O)COC(C)=O GOQRKXBLBLOWLQ-UHFFFAOYSA-N 0.000 description 4
- YFRQHPSVKZAVQC-UHFFFAOYSA-N COC(=O)COC(C)=O.COC(C)=O Chemical compound COC(=O)COC(C)=O.COC(C)=O YFRQHPSVKZAVQC-UHFFFAOYSA-N 0.000 description 4
- KXKVLQRXCPHEJC-UHFFFAOYSA-N COC(C)=O Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 4
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F22/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides or nitriles thereof
- C08F22/10—Esters
- C08F22/12—Esters of phenols or saturated alcohols
- C08F22/14—Esters having no free carboxylic acid groups
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Definitions
- the present invention relates to a novel method for the preparation of nanoparticles formed from a polymerised methylidene malonate compound, said nanoparticles, optionally containing one or more biologically active molecules, as well as to pharmaceutical compositions containing them.
- Nanoparticles is understood as meaning sub-micron particles having a diameter of less than about 500 nanometres. Nanoparticles formed by emulsion polymerisation of an alkyl cyanoacrylate are described in the EP 0 007 895 patent. The method used in the preparation of these alkyl cyanoacrylate particles relies on the (anionic) polymerisation of the monomer which takes place spontaneously and in an aqueous medium. The preparation which follows the same principle (anionic emulsion polymerisation) of nanoparticles constituted of a methylidene malonate polymer is described notably in F. Lescure et al, Pharm. Res., 1994, 11, 1270-1276.
- the emulsion polymerisation of methylidene malonates in the form of nanoparticles leads, in aqueous phase and at slightly acid pH, to the formation of oligomers, mainly of the trimer or tetramer type, which are highly biodegradable. These molecular species are partially hydrosoluble, such that the dispersion of these nanoparticles in an aqueous medium leads to their solubilisation and to the rapid loss of the particle structure (P. Breton et al., Eur. J. Pharm. Biopharm., 1996, 42, 95-103).
- polymers of average molecular mass between about 5000 and 10000, notably about 8000,
- the present invention therefore consists of the preparation of methylidene malonate nanoparticles having a diameter of less than 500 nm, in particular 100 to 500 nm. formed from homogeneous molecular species of wide-ranging masses (Mw between about 2000 and 80000).
- the principle consists in dissolving the monomer in a water-miscible aprotic organic phase but which, under the conditions of preparation of the nanoparticles, forms, with the aqueous polymerisation medium, a non-solvent mixture of the polymer formed.
- Aprotic organic phase or “aprotic organic solvent”, is understood as meaning an organic phase or a solvent without labile proton which is capable of initiating an anion.
- the method enables the use of dispersing agents such as non-ionic surfactants or colloid protecting polymers, which leads to particles having flexible surface properties.
- the invention relates to a method for the preparation of nanoparticles formed from a random polymer of at least one compound of formula (I)
- A represents a
- R 1 and R 2 identical or different, represent a linear or branched C 1 -C 6 alkyl group
- n 1, 2, 3, 4 or 5;
- the monomer(s) is (are), before the polymerisation, dissolved in a water-miscible aprotic organic solvent forming, with the polymerisation medium, a non-solvent mixture of the polymer formed.
- the invention relates to a method for the preparation of nanoparticles formed from a polymer of a compound of formula (I)
- R 1 and R 2 identical or different, represent a linear or branched C 1 -C 6 alkyl group
- n 1, 2, 3, 4 or 5;
- the method according to the invention enables the preparation of nanoparticles having a diameter of less than 500 nm, preferably between 100 and 500 nm. and an average molecular mass (Mw) between about 1000 and 100000, notably between about 1000 and 80000. in particular between about 2000 and 80000, preferably between about 8000 and 80000.
- Mw average molecular mass
- the method according to the invention comprises the steps consisting in:
- the aqueous polymerisation medium can also be added to the organic phase which contains the monomer dissolved beforehand, and according to another aspect, the method according to the invention comprises the steps consisting in
- the pH of the polymerisation medium is selected as a function of the molecular mass of the polymer that is desired to prepare.
- the mixture of the organic phase and the aqueous medium is homogenised by continuous stirring for about 30 minutes and then, optionally, the preparation is completed by distilled water.
- the polymer formed precipitates in the polymerisation medium and can be recovered by filtration for example.
- the nanoparticle suspension thus obtained can then be conditioned and lyophilised.
- the aprotic organic solvent used for dispersing the monomer(s) must be a solvent of said monomer(s) which should also be miscible with water.
- This solvent is preferably selected from acetone, acetonitrile, dioxane and tetrahydrofuran. acetone being particularly preferred.
- the concentration of monomer(s) of formula (I) in the organic solvent is of the order 30 mg/ml to 150 mg/ml;
- the molarity of the polymerisation medium is of the order of ⁇ fraction (1/30) ⁇ M to 1 ⁇ 3M;
- volume ratio of the aqueous phase to the organic phase is between 3/1 and 20/1, preferably between 3/1 and 15/1.
- the polymerisation medium contains one or more surfactants or colloid protectors.
- the surfactants can be ionic or non-ionic surfactants for example.
- Non-ionic surfactants will preferably be used which are selected from copolymers of polyoxyethylene and polyoxypropylene, poloxamers and polysorbates.
- colloid protector agents polysaccharide derivatives will preferably be used, such as dextrans, hydrosoluble cellulose derivatives: polyethylene glycols poly(vinyl alcohol).
- the compound polymerised to form the nanoparticles according to the method of the invention is a compound of formula (I) in which : A represents a
- the compound polymerised to form the nanoparticles according to the method of the invention is a compound of formula (I) in which: A represents a
- group as defined above can also be random polymerised.
- the invention relates to the nanoparticles formed from a random polymer of at least one methylidene malonate compound of formula (I), having a diameter of less than 500 nm, preferably between 100 and 500 nm and an average molecular mass (Mw) between about 1000 and 100000, notably between 1000 and 80000, in particular between about 2000 and 80000, preferably between about 8000 and 80000, obtainable by this method.
- Mw average molecular mass
- said nanoparticles are formed from a polymer of a compound of formula (I), have a diameter of less than 500 nm, preferably between 100 and 500 nm and an Mw between about 1000 and 80000, in particular between about 2000 and 80000, preferably between about 8000 and 80000.
- the invention relates to nanoparticles formed from a random polymer of at least one compound of formula (I), having a diameter of less than 500 nm. preferably between 100 and 500 nm and an average molecular mass (Mw) between about 8000 and 100000, preferably between about 8000 and 80000.
- the invention relates to nanoparticles formed from a polymer of a compound of formula (I), having a diameter of less than 500 nm, preferably between 100 and 500 nm and an average molecular mass (Mw) between about 8000 and 80000.
- said nanoparticles are formed from a compound of formula (I) in which A represents a
- said nanoparticles are formed from a compound of formula (I) in which A represents a
- said nanoparticles can be constituted of a random polymer of a mixture of compounds of formula (I) in which A is a
- said nanoparticles comprise, in their polymeric network, one or more biologically active molecules such as mentioned above.
- the organic phase when it is a biologically active molecule which is insoluble in water
- the polymerisation medium can contain one or more biologically active molecules.
- Bioly active molecule is understood as meaning, in a non-limiting way, any molecule or macromolecule which has a prophylactic or curative biological activity, in vitro or in vivo, notably an anti-infectious agent, in particular an antiseptic agent, an antibiotic, an antiviral, an antiparasitic or antimitotic agent, notably an anticancer agent.
- Antibiotic or antiseptic agents which can be used can be, for example, rifampicin and colistin.
- didanosin, ribavirin, zidovudin, acyclovir, ganciclovir, foscarnet, vidarabin and zalcitabin can be cited in a non-limiting way.
- Cis-plastin, 5-fluorouracil or taxol can, for example, be used as anti-cancer agents.
- Another advantageous antitumor agent is creatine phosphate whose activity is described in the application EP 0 614 366.
- the invention also relates to pharmaceutical compositions containing said nanoparticles which comprise one or more biologically active molecules in association with a pharmaceutically acceptable vehicle.
- compositions according to the invention can be compositions which can be administered for example orally, sublingually, subcutaneously, intramuscularly, intravenously, transdermally, locally, rectally, via the pulmonary route, or nasally.
- the suitable forms of administration notably comprise oral forms, such as tablets, gelatine capsules, powders, granules and oral solutions or suspensions, sublingual and buccal administration forms, as well as subcutaneous, intramuscular, intravenous, intranasal or intraocular and rectal administration forms.
- the invention is illustrated by the Examples below, in which the preparation of the particles is carried out at ambient temperature (about 21° C.).
- the size, or diameter, of the nanoparticles was measured with a laser diffusion counter (Coulter Electronic Inc., USA).
- the molecular mass of the polymers was determined by gel permeation chromatography.
- the nanoparticle suspension 50 ml of distilled water containing 2.5 g of glucose or trehalose (colloid protectors and cryoprotectors) are added to the nanoparticle suspension and the mixture is submitted to an evaporation in vacuo so as to remove the acetone and to reduce the volume of the aqueous suspension to 50 ml.
- the preparation After filtration on filter paper (pore diameter 5 to 15 ⁇ m), the preparation is lyophilised. As measured by laser diffusion, the particles contained in the filtrate have a diameter of 288 nm.
- the average molecular mass (Mw) of the methylidene malonate constituting the polymer matrix of the particles is evaluated to be 67000 by gel permeation chromatography.
- the gel permeation chromatographic profile of FIG. 1 represents the distribution of the molecular mass of the polymer prepared at pH 5.5 (concentration: 90 mg/ml). A broad peak is observed in 1 which corresponds to the species of high average molecular mass (Mw) and a narrow peak is observed in 2 which corresponds to the minor oligomers (major trimers and tetramers).
- Peak F is that of toluene used as internal standard and the negative peak correspond to traces of water.
- Nanoparticles are prepared according to Examples 1 to 3 and are compared to the nanoparticles prepared according to the method described by Lescure et al., Pharm. Res. 1994.11, 1270-1276. For this. 100 mg of monomer are introduced with stirring in 10 ml of a phosphate buffer medium (Na 2 HPO 4 /KH 2 PO 4. 1/15 M) of pH 5 to 8.
- a phosphate buffer medium Na 2 HPO 4 /KH 2 PO 4. 1/15 M
- the average molecular mass (Mw) of the polymers constituting the nanoparticles prepared according to Lescure et al. is less than that of the polymer obtained according to the method of the invention
- the contents of the oligomers (trimers-tetramers) constituting the polymers are significantly less for the nanoparticles prepared according to the method of the invention.
- the yields of polymerisation in the form of nanoparticles are higher for the method of the invention compared to the method according to Lescure et al (the formation of aggregates results in low yields at basic pH for the method according to Lescure et al.).
- the yield is determined by the ratio of the amount of monomer introduced into the reaction medium and the amount of polymer constituting the nanoparticles.
- the experiment is carried out following the method of Example 1, but using acetone, acetonitrile or tetrahydrofuran (THF) as solvent of the monomer.
- THF tetrahydrofuran
- the polymerisation is instantaneous.
- the stirring is maintained for 30 minutes after the introduction of the whole of the organic phase.
- 10 ml of distilled water are added to the nanoparticle suspension, and the mixture is submitted to an evaporation in vacuo so as to remove the acetone.
- the experimental protocol is identical to that of test 3 but the Dextran 70 is replaced with Pluronic F68. After centrifugation, the nanoparticles contained in the plug are analysed by steric exclusion chromatography to determine their weight average molecular mass (Mw).
- the size of the nanoparticles and the rifampicin concentration are measured before and after lyophilisation.
- the size is measured by laser diffusion.
- the determination of the rifampicin is carried out by high performance liquid chromatography coupled to a spectrophotometer.
- the mobile phase is composed of a mixture of methanol/0.05 M ammonium acetate (65:35).
- the pH is adjusted to 7.3, the flow rate is fixed at 1 ml/min and the absorption is read at 254 nm.
- the content of rifampicin which is not bound to the nanoparticles is measured in the supernatant obtained after ultracentrifugation of the nanoparticle suspension (80000 g. 1 h at 4° C.).
- the amount of rifampicin bound to the nanoparticles corresponds to the fraction present in the plug, which is dissolved in THF before proceeding with the direct rifampicin determination.
- nanoparticles containing rifampicin 266 ⁇ 63 nm before lyophilisation and 282 ⁇ 54 nm after lyophilisation;
- Example 12 The experiment is carried out in the same way as in Example 12, but the active principle being hydrosoluble, it is incorporated in the polymerisation medium at a concentration of 0.5 mg/ml before addition of the organic phase.
- the size of the nanoparticles containing colistin measured by laser diffusion is 282 ⁇ 65 nm after evaporation and 283 ⁇ 26 nm after conservation at +4° C. for 4 days. Determined according to the gelose diffusion technique (S. P. Gotoff et al., Antimicrob.
- colistin is found at the concentration of 15 ⁇ g/ml in the supernatant obtained after ultracentrifugation of the nanoparticle suspension (80000 g, 1 hour at 4° C.): the fraction which is not bound to the nanoparticles is then evaluated at 3% of the total amount of colistin added.
- the size of the nanoparticles containing AZT measured by laser diffusion is 255 ⁇ 63 nm before lyophilisation.
- the content of AZT in the supernatant after centrifugation of the nanoparticle suspension (12000 rpm, 1 hour at 4° C.) is determined by UV spectrophotometry at 266 nm.
- a concentration of 98 ⁇ g/ml is obtained: the fraction which is not bound to the nanoparticles is therefore evaluated to be 31.9% of the total amount of AZT added.
- the fraction of AZT bound to the nanoparticles is therefore 68.1%.
- the encapsulation of creatine phosphate is carried out according to the technique of Example 14.
- the size of the nanoparticles containing creatine phosphate measured by laser diffusion is 275 ⁇ 260 nm before lyophilisation.
- the determination of the creatine phosphate is carried out by high performance liquid chromatography coupled to a spectrophotometer.
- the mobile phase is composed of a phosphate buffer (KH 2 PO 4. 0.05 M) adjusted to pH 3.3.
- the flow rate is fixed at 2 ml/min and the absorption is read at 200 nm.
- the content of creatine phosphate which is not bound to the nanoparticles is measured in the supernatant obtained after centrifugation of the nanoparticle suspension (12000 rpm, 1 hour at 4° C.).
- the creatine phosphate is found at a concentration of 463 ⁇ g/ml in the supernatant: the fraction which is not bound to the nanoparticles is therefore evaluated at 81% of the total amount of creatine phosphate added.
- the fraction of creatine phosphate bound to the nanoparticles is therefore 19%.
- the encapsulation of 5-FU (Sigma Aldrich Chimie, France) is carried out according to the technique of Example 14.
- the size of the nanoparticles containing the 5-FU measured by laser diffusion is 516 ⁇ 88 nm before lyophilisation. Determined by UV spectrophotometry at 266 nm, the 5-EU is found at a concentration of 70 ⁇ g/ml in the supernatant obtained after centrifugation of the nanoparticle suspension (12 000 rpm, 1 hour at 4° C.): the fraction which is not bound to the nanoparticles is therefore evaluated at 23.3% of the total amount of 5-FU added. The fraction of 5-FU bound to the nanoparticles is therefore 76.7%.
Abstract
The invention relates to a method for the preparation of nanoparticles formed from a random polymer of at least one compound of formula (I)
group
R1 and R2, identical or different, represents a linear or branched C1-C6 alkyl group;
n=1, 2, 3, 4 or 5,
characterised in that the monomer is dissolved beforehand in a water-miscible aprotic organic solvent forming, with the polymerization medium, a non-solvent mixture of the polymer formed.
The invention also relates to said nanoparticles, which optionally contain one or more biologically active molecules, and the pharmaceutical compositions containing them.
Description
- The present invention relates to a novel method for the preparation of nanoparticles formed from a polymerised methylidene malonate compound, said nanoparticles, optionally containing one or more biologically active molecules, as well as to pharmaceutical compositions containing them.
- “Nanoparticles” is understood as meaning sub-micron particles having a diameter of less than about 500 nanometres. Nanoparticles formed by emulsion polymerisation of an alkyl cyanoacrylate are described in the EP 0 007 895 patent. The method used in the preparation of these alkyl cyanoacrylate particles relies on the (anionic) polymerisation of the monomer which takes place spontaneously and in an aqueous medium. The preparation which follows the same principle (anionic emulsion polymerisation) of nanoparticles constituted of a methylidene malonate polymer is described notably in F. Lescure et al, Pharm. Res., 1994, 11, 1270-1276. These monomers, whose preparation is described in the EP 0 283 364 patent, have a structure close to that of the cyanoacrylates but the nitrile function of the latter is replaced with an ester or an ester ester. Like the cyanoacrylates, they polymerise in the cold in an aqueous medium and can be biodegradable.
- However, the methylidene malonate nanoparticles thus obtained possess certain drawbacks.
- In fact, the emulsion polymerisation of methylidene malonates in the form of nanoparticles leads, in aqueous phase and at slightly acid pH, to the formation of oligomers, mainly of the trimer or tetramer type, which are highly biodegradable. These molecular species are partially hydrosoluble, such that the dispersion of these nanoparticles in an aqueous medium leads to their solubilisation and to the rapid loss of the particle structure (P. Breton et al., Eur. J. Pharm. Biopharm., 1996, 42, 95-103). When a biologically active molecule is associated with the methylidene malonate nanoparticles, is therefore possible for the molecule to be released very rapidly after the administration, following the effect of dilution in the circulatory current which brings about the rapid solubilisation of the oligomers which form the particle matrix, before eventually arriving at the site of action of the active principle.
- Certain experiments have shown that the polymerization at basic pH enabled the formation of polymers of higher molecular masses while maintaining the size of the nanoparticles. However, such syntheses are characterised by:
- the impossibility of obtaining polymers of Mw<10 000, and a fortiori Mw<8000. constituting individualised nanoparticles, without forming aggregates and without the significant presence of oligomeric species.
- the impossibility of constituting polymers of Mw>20 000 and a fortiori of higher Mw, at high pH (pH>7) without the inevitable formation of aggregates which render the intravascular administration of these preparations impossible.
- “Mw” is understood as meaning the mass average molecular mass (or average molecular mass) defined as: Mw=Σni.Mi2 /Σni.Mi and Mp means the molecular mass of the quantitatively major species.
- In the rest of the description, the molecular mass is expressed in polystyrene equivalents (Ep).
- This preparative method is therefore not suitable if it is desired to prepare methylidene malonate nanoparticles constituted of:
- polymers of average molecular mass between about 5000 and 10000, notably about 8000,
- polymers of average molecular mass greater than 20000, without forming aggregates.
- The present invention therefore consists of the preparation of methylidene malonate nanoparticles having a diameter of less than 500 nm, in particular 100 to 500 nm. formed from homogeneous molecular species of wide-ranging masses (Mw between about 2000 and 80000). The principle consists in dissolving the monomer in a water-miscible aprotic organic phase but which, under the conditions of preparation of the nanoparticles, forms, with the aqueous polymerisation medium, a non-solvent mixture of the polymer formed.
- “Aprotic organic phase” or “aprotic organic solvent”, is understood as meaning an organic phase or a solvent without labile proton which is capable of initiating an anion.
- The advantages of this preparative method according to the invention are numerous:
- it enables a more homogeneous dispersion of the monomer in the polymerisation medium,
- it makes use of non-chlorinated solvents which are easy to evaporate since they are volatile,
- it prevents the formation of polymer aggregates,
- it gives rise to high polymerisation yields,
- it enables the constitution of polymers of homogeneous wide-ranging molecular mass (Mw about 2000 to 100000, notably about 2000 to 80000) in forming nanoparticles having a diameter of less than 500 nm.
- Furthermore, the method enables the use of dispersing agents such as non-ionic surfactants or colloid protecting polymers, which leads to particles having flexible surface properties.
- Finally, the molecular mass of the oligomers/polymers which form the nanoparticles according to the invention can be perfectly mastered by adjusting the following preparative conditions:
- the monomer concentration in the organic phase,
- the pH and the molarity of the polymerisation medium,
- the nature and the concentration of the dispersing agent,
- the volume ratio of the aqueous phase (polymerisation medium)/organic phase,
- the mode of introduction of the organic mixture in the aqueous phase.
-
- in which
-
- group;
- R1 and R2, identical or different, represent a linear or branched C1-C6 alkyl group;
- n=1, 2, 3, 4 or 5;
- characterised in that the monomer(s) is (are), before the polymerisation, dissolved in a water-miscible aprotic organic solvent forming, with the polymerisation medium, a non-solvent mixture of the polymer formed.
-
- group;
- R1 and R2, identical or different, represent a linear or branched C1-C6 alkyl group;
- n=1, 2, 3, 4 or 5;
- characterised in that before the polymerisation, the monomer is dissolved in a water-miscible aprotic organic solvent forming, with the polymerisation medium, a non-solvent mixture of the polymer formed.
- According to a particular aspect, the method according to the invention enables the preparation of nanoparticles having a diameter of less than 500 nm, preferably between 100 and 500 nm. and an average molecular mass (Mw) between about 1000 and 100000, notably between about 1000 and 80000. in particular between about 2000 and 80000, preferably between about 8000 and 80000.
- In particular, the method according to the invention comprises the steps consisting in:
- preparing a solution of at least one compound of formula (I) in a water-miscible aprotic organic solvent.
- adding, with stirring, this organic phase to an aqueous polymerisation medium at a pH between 4.5 and 10,
- recovering the nanoparticles thus obtained after homogenisation of the mixture and evaporating the organic solvent in vacuo.
- The aqueous polymerisation medium can also be added to the organic phase which contains the monomer dissolved beforehand, and according to another aspect, the method according to the invention comprises the steps consisting in
- preparing a solution of at least one compound of formula (I) in a water-miscible aprotic organic solvent,
- adding, with stirring, to this organic phase, an aqueous polymerisation medium at a pH between 4.5 and 10,
- recovering the nanoparticles thus obtained after homogenisation of the mixture and evaporating the organic solvent in vacuo.
- As illustrated later on in the Examples, the pH of the polymerisation medium is selected as a function of the molecular mass of the polymer that is desired to prepare.
- Advantageously, the mixture of the organic phase and the aqueous medium is homogenised by continuous stirring for about 30 minutes and then, optionally, the preparation is completed by distilled water.
- The polymer formed precipitates in the polymerisation medium and can be recovered by filtration for example. The nanoparticle suspension thus obtained can then be conditioned and lyophilised.
- The aprotic organic solvent used for dispersing the monomer(s) must be a solvent of said monomer(s) which should also be miscible with water. This solvent is preferably selected from acetone, acetonitrile, dioxane and tetrahydrofuran. acetone being particularly preferred.
- Preferred aspects of the method are the following:
- the concentration of monomer(s) of formula (I) in the organic solvent is of the
order 30 mg/ml to 150 mg/ml; - the molarity of the polymerisation medium is of the order of {fraction (1/30)}M to ⅓M;
- volume ratio of the aqueous phase to the organic phase is between 3/1 and 20/1, preferably between 3/1 and 15/1.
- Advantageously, the polymerisation medium contains one or more surfactants or colloid protectors.
- The surfactants can be ionic or non-ionic surfactants for example. Non-ionic surfactants will preferably be used which are selected from copolymers of polyoxyethylene and polyoxypropylene, poloxamers and polysorbates. As colloid protector agents, polysaccharide derivatives will preferably be used, such as dextrans, hydrosoluble cellulose derivatives: polyethylene glycols poly(vinyl alcohol).
-
- group, n=1 and R1=R2=ethyl.
-
- group, and R1=R2=propyl.
-
- group as defined above, can also be random polymerised.
- In a 2nd aspect, the invention relates to the nanoparticles formed from a random polymer of at least one methylidene malonate compound of formula (I), having a diameter of less than 500 nm, preferably between 100 and 500 nm and an average molecular mass (Mw) between about 1000 and 100000, notably between 1000 and 80000, in particular between about 2000 and 80000, preferably between about 8000 and 80000, obtainable by this method.
- In particular, said nanoparticles, obtainable by this method, are formed from a polymer of a compound of formula (I), have a diameter of less than 500 nm, preferably between 100 and 500 nm and an Mw between about 1000 and 80000, in particular between about 2000 and 80000, preferably between about 8000 and 80000.
- In a preferred aspect, the invention relates to nanoparticles formed from a random polymer of at least one compound of formula (I), having a diameter of less than 500 nm. preferably between 100 and 500 nm and an average molecular mass (Mw) between about 8000 and 100000, preferably between about 8000 and 80000.
- In particular, the invention relates to nanoparticles formed from a polymer of a compound of formula (I), having a diameter of less than 500 nm, preferably between 100 and 500 nm and an average molecular mass (Mw) between about 8000 and 80000.
-
- group, n=1 and R1=R2=ethyl.
-
- group and R1=R2=propyl.
-
- group as defined above.
- According to a further aspect of the invention, said nanoparticles comprise, in their polymeric network, one or more biologically active molecules such as mentioned above.
- In fact, in an advantageous aspect of the method according to the invention, the organic phase (when it is a biologically active molecule which is insoluble in water) or the polymerisation medium can contain one or more biologically active molecules.
- “Biologically active molecule” is understood as meaning, in a non-limiting way, any molecule or macromolecule which has a prophylactic or curative biological activity, in vitro or in vivo, notably an anti-infectious agent, in particular an antiseptic agent, an antibiotic, an antiviral, an antiparasitic or antimitotic agent, notably an anticancer agent.
- Antibiotic or antiseptic agents which can be used can be, for example, rifampicin and colistin.
- As antiviral agents, didanosin, ribavirin, zidovudin, acyclovir, ganciclovir, foscarnet, vidarabin and zalcitabin can be cited in a non-limiting way.
- Cis-plastin, 5-fluorouracil or taxol can, for example, be used as anti-cancer agents. Another advantageous antitumor agent is creatine phosphate whose activity is described in the application EP 0 614 366.
- The invention also relates to pharmaceutical compositions containing said nanoparticles which comprise one or more biologically active molecules in association with a pharmaceutically acceptable vehicle.
- The compositions according to the invention can be compositions which can be administered for example orally, sublingually, subcutaneously, intramuscularly, intravenously, transdermally, locally, rectally, via the pulmonary route, or nasally.
- The suitable forms of administration notably comprise oral forms, such as tablets, gelatine capsules, powders, granules and oral solutions or suspensions, sublingual and buccal administration forms, as well as subcutaneous, intramuscular, intravenous, intranasal or intraocular and rectal administration forms.
- The invention is illustrated by the Examples below, in which the preparation of the particles is carried out at ambient temperature (about 21° C.). The size, or diameter, of the nanoparticles was measured with a laser diffusion counter (Coulter Electronic Inc., USA). The molecular mass of the polymers was determined by gel permeation chromatography.
- 500 mg of 1-ethoxycarbonyl-1-ethoxycarbonylmethyleneoxycarbonylethene (Laboratoires UPSA/CARPIBEM, France), already desorbed of SO2 for 3 hours under 25 mbars. are dissolved in 5.55 ml acetone. This solution is then mixed gradually and under magnetic stirring with 50 ml of an aqueous medium buffered at pH 8 (Na2HPO4/KH2PO4.1/15 M) and containing 500 mg of dextran 70 (FLUKA CHEMIE, Switzerland). The almost instant polymerisation produces a cloudiness of the mixture which possesses a Tyndall effect characteristic of colloidal solutions. Stirring is maintained for 30 minutes after the complete introduction of the organic phase. Next. 50 ml of distilled water containing 2.5 g of glucose or trehalose (colloid protectors and cryoprotectors) are added to the nanoparticle suspension and the mixture is submitted to an evaporation in vacuo so as to remove the acetone and to reduce the volume of the aqueous suspension to 50 ml. After filtration on filter paper (pore diameter 5 to 15 μm), the preparation is lyophilised. As measured by laser diffusion, the particles contained in the filtrate have a diameter of 288 nm. The average molecular mass (Mw) of the methylidene malonate constituting the polymer matrix of the particles is evaluated to be 67000 by gel permeation chromatography.
- The experiment is carried out following the technique described in Example 1, but only varying the pH only of the phosphate buffer. The results are given in Table 1 below, in which Mp is the molecular mass of the principal species and Mw is the average molecular mass of the polymer.
TABLE 1 pH of the polymerisation medium 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 size (nm) 280 344 424 423 361 382 313 288 standard 9 9 7 6 9 7 2 3 deviation +/− nm characteristics of the polymer (Ep) Mp 662 655 655 19700 31500 36900 40300 59300 Mw 2080 4740 11140 17600 28900 39000 53200 67200 - The results show that the average molecular mass of the polymers which constitute the nanoparticles increase regularly with the pH of the polymerisation medium.
- The gel permeation chromatographic profile of FIG. 1 represents the distribution of the molecular mass of the polymer prepared at pH 5.5 (concentration: 90 mg/ml). A broad peak is observed in 1 which corresponds to the species of high average molecular mass (Mw) and a narrow peak is observed in 2 which corresponds to the minor oligomers (major trimers and tetramers).
- The dotted lines limit the analysable portion of the chromatogram. Peak F is that of toluene used as internal standard and the negative peak correspond to traces of water.
- The experiment is carried out following the technique described in Example 1, but by varying only the monomer concentration in acetone. The results are given in Table 2 below:
TABLE 2 monomer concentration in the organic phase (mg/ml) 30 60 90 size (nm) 213 239 288 standard deviation 2 4 3 +/− nm characteristics of the polymer (Ep) Mp 31500 39600 59300 Mw 44700 63000 67200 - The results show that the molecular mass of the principal species (Mp), as well as the average molecular mass (Mw) of the polymers which constitute the nanoparticles, increase regularly with the concentration of the monomer in the organic phase.
- The experiment is carried out according to Examples 1 to 3 but in replacing
dextran 70 colloid protector with a non-ionic surfactant, Pluronic F68 (BASF Corporation, USA). - The results are given in Table 3 below.
TABLE 3 pH of the polymerisation medium containing 0.5% Pluronic F 68 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 Size (nm) 87 80 95 117 122 121 146 153 standard 1 2 2 5 9 1 3 1 deviation +/− nm characteristics of the polymer (Ep)* Mp 656 13300 14800 25600 38600 43700 45300 77800 Mw 5520 9740 12300 23600 33000 51600 70900 88900 - The results show, for the same conditions of pH:
- an increase in the molecular mass of the principal species (Mp) and in the average molecular mass (Mw) of the polymers constituting the nanoparticles in the presence of the surfactant with respect to the colloid protector,
- a decrease in the size of these same nanoparticles in the presence of the surfactant with respect to the colloid protector.
- According to the method described in Example 1, 500 mg of monomer are dissolved in 16.6 ml acetone are introduced into a phosphate buffer (Na2HPO4/KH2PO4) of increasing molarity, and further containing 0.5% Pluronic F68.
- The results are given in Table 4 below:
TABLE 4 standard size of the deviation Mp Mw molarity nanoparticles (nm) (nm) (Ep) (Ep) 0.033 M 127 2 15200 12500 0.066 M 123 1 14600 12400 0.133 M 124 1 653 9790 0.267 M 179 3 660 8690 - The results show a decrease in the average molecular mass (Mw) of the polymers which constitute the nanoparticles in proportion to an increase in the molarity of the medium.
- Nanoparticles are prepared according to Examples 1 to 3 and are compared to the nanoparticles prepared according to the method described by Lescure et al., Pharm. Res. 1994.11, 1270-1276. For this. 100 mg of monomer are introduced with stirring in 10 ml of a phosphate buffer medium (Na2HPO4/KH2PO4.1/15 M) of pH 5 to 8.
- The results are given in Table 5 below in which the oligomers are defined as any molecular species of molecular mass less than or equal to 920.
TABLE 5 pH of the polymerisation medium containing 1 % dextran 705.5 6.0 6.5 7.0 7.5 8.0 Method according size (nm) 260 296 337 335 271 322 to Lescure et standard 5 5 10 4 6 6 al., 1994 deviation +/− nm Mp 666 660 675 685 15572 13000 Mw 1719 2421 5335 6041* 6759* 7594* % oligomers 43 53 27 38 18 13 yield of 87 79.5 71.5 59.5 21 23 nanoparticles obtained % ±5 Method according size (nm) 424 423 361 382 313 288 to the invention** standard 7 6 9 7 2 3 deviation +/− nm Mp 655 19695 31508 36290 40278 59300 Mw 11138 17569 28918 38997 53181 67201 % oligomers 19 14 8 4 3 2 yield of 82.5 73 84.5 91 85 86.5 nanoparticles obtained % ±5 - The results show that, for any experimental condition of identical pH
- the average molecular mass (Mw) of the polymers constituting the nanoparticles prepared according to Lescure et al. is less than that of the polymer obtained according to the method of the invention;
- the contents of the oligomers (trimers-tetramers) constituting the polymers are significantly less for the nanoparticles prepared according to the method of the invention;
- the yields of polymerisation in the form of nanoparticles are higher for the method of the invention compared to the method according to Lescure et al (the formation of aggregates results in low yields at basic pH for the method according to Lescure et al.).
- The gel permeation chromatography profile of FIG. 2 represents the distributions of molecular mass of the polymers prepared at pH 7.5 according to the method of the invention on the one hand (trace A), and according to the method of Lescure et al on the other (trace B). Apart from peak 3 corresponding to toluene, for peak A, a
single peak 1 is observed which corresponds to the principal species (Mp=40278) while for trace B, the presence of asignificant peak 2 is observed also which corresponds to the oligomers (trimers and tetramers). - 50 ml of an aqueous medium buffered at pH 5; 6.5 or 8 (Na2HPO4/KH2PO4 1/15 M) and containing 0.5% of Pluronic F68 (BASF Corporation, USA) are added gradually and with magnetic stirring to 5.55 ml of a solution of 500 mg of 1-ethoxycarbonyl-1-ethoxycarbonylmethyleneoxy-carbonylethene monomer (LABORATOIRES UPSA/CARPIBEM, France), already desorbed of SO2 for 3 hours under 25 mbars in 5.55 ml of acetone. The stirring is maintained for 16 hours for the tests at pH 5 and 6.5 or for 30 minutes for the test at pH 8 after the complete introduction of the organic phase. Next, 50 ml of distilled water containing 2.5 g of glucose or trehalose (colloid protectors and cryoprotectors) are added to the nanoparticle suspension and the mixture is submitted to evaporation in vacuo so as to remove the acetone and to reduce the volume of the aqueous suspension to 50 ml. After filtration on filter paper (pore diameter 5 to 15 μm), the preparation is lyophilised. The diameter of the particles contained in the filtrate is measured by laser diffusion. The average molecular mass (Mw) of the methylidene malonate constituting the polymer matrix of the particles is evaluated by gel permeation chromatography.
- The results are given in Table 6 below, in which Mp is the molecular mass of the principal species and Mw is the average molecular mass of the polymer.
- The yield is determined by the ratio of the amount of monomer introduced into the reaction medium and the amount of polymer constituting the nanoparticles.
TABLE 6 pH of the polymerisation medium 5.0 6.5 8.0 size (nm) 848 394 754 standard deviation 36 32 34 +/−nm characteristics of the polymer (Ep) Mp 312 24300 26500 Mw 6450 20100 20100 yield % 59 57 30 standard deviation 5.1 4.6 4.2 - The experiment is carried out following the method of Example 1, but using acetone, acetonitrile or tetrahydrofuran (THF) as solvent of the monomer.
- The results are given in Table 7 below.
TABLE 7 Average particle Solvent size (nm) yield (%) Mw Acetone 253 74 54 100 Acetonitrile 197 69 31 700 THF 191 70 30 300 - The experiment is carried out following the method of Example 1, but varying the water/acetone volume ratio.
- The results are given in Table 8 below:
TABLE 8 Water/solvent volume ratio 4.5/1 9/1 18/1 size (nm) 241 288 334 yield (%) 74 74 85 characteristics of the polymer Mp 62100 59300 33100 Mw 42000 67200 24600 - The tests were carried out in an aqueous medium at pH=10 in the presence either of a surfactant or a colloid protector and this, either following the method of Example 1 or following the method of Example 7.
- 1)
test 1 - 100 mg of 1-ethoxycarbonyl-1-ethoxycarbonylmethyleneoxycarbonyl-ethene monomer are dissolved in 1 ml of acetone.
- This solution is then added gradually and with magnetic stirring into 10 ml of an aqueous medium at pH=10 and containing 100 mg of
Dextran 70. - The polymerisation is instantaneous. The stirring is maintained for 30 minutes after the introduction of the whole of the organic phase. Next, 10 ml of distilled water are added to the nanoparticle suspension, and the mixture is submitted to an evaporation in vacuo so as to remove the acetone. The medium is then centrifuged (v=10 000 rpm. 10 min at 4° C.).
- 2)
test 2 - The experimental protocol is identical to that of
test 1 but by replacingDextran 70 with Pluronic F68. - 3) test 3
- 10 ml of an aqueous medium at pH=10 containing 100 mg of
Dextran 70 are added gradually with magnetic stirring into an organic phase constituted of 100 mg of monomer and 1 ml of acetone. The polymerisation is instantaneous. The stirring is maintained for 30 minutes after the introduction of the whole of the aqueous phase. Next, 10 ml of distilled water are added to the nanoparticle suspension and the mixture is submitted to an evaporation in vacuo so as to remove the acetone. The medium is then centrifuged (v=10 000 rpm. 10 min at 4° C.). - 4) test 4
- The experimental protocol is identical to that of test 3 but the
Dextran 70 is replaced with Pluronic F68. After centrifugation, the nanoparticles contained in the plug are analysed by steric exclusion chromatography to determine their weight average molecular mass (Mw). - The results are given in the Table 9 below.
TABLE 9 Mw Particle size (nm) Test 18 800 240 Test 26 900 245 Test 3 1 400 316 Test 4 1 850 333 - The experiment is carried out following the polymerisation technique described in Example 1, but using 1,1-propoxycarbonylethene (Laboratoires UPSA/CARPIBEM, France) hereinafter referred to as MM 3.3 alone or in a mixture with the 1-ethoxycarbonyl-1-ethoxycarbonylmethyleneoxy-carbonylethene monomer (Laboratoires UPSA/CARPIBEM. France), hereinafter referred to as MM 2.1.2. The results are given in Table 10 below, in which Mp is the molecular mass of the principal species and Mw is the average molecular mass of the polymer.
TABLE 10 Ratio MM 3.3/MM 2.1.2 100/0 75/25 50/50 25/75 Size 123 223 298 155 Yield (%) 77 73 80 78 Characteristics of the polymer Mp 44764 92090 37467 21727 Mw 44122 89793 37467 21727 - 5 mg of rifampicin base (Sigma) are dissolved in 1 ml of acetone to which 90 mg of 1-ethoxycarbonyl-1-ethoxycarbonyl methyleneoxy-carbonylethene monomer (LABORATOIRES UPSA/CARPIBEM. France) are added, beforehand desorbed of SO2 for 3 hours under 25 mbars. With the aid of a glass pipette, this solution is then added gradually and with constant stirring (750 rpm) to 9 ml of aqueous medium buffered at pH 6.0 with the aid of a phosphate buffer (Na2HPO4/KH2PO4 0.066 M) and containing 90 mg of dextran 70 (1% w/v). After 18 hours of polymerisation at 20° C., 9 ml of distilled water containing 5% of D-glucose are added with stirring to the nanoparticle suspension, the mixture is then submitted to an evaporation in vacuo with the aid of a Rotavapor (20° C., 25 mbars) so as to remove the acetone and to reduce the volume of the aqueous suspension to 9 ml. The preparation is then lyophilised: freezing takes place at −30° C. and sublimation at +20° C. for 36 hours at a pressure of 0.05 mbar.
- The size of the nanoparticles and the rifampicin concentration are measured before and after lyophilisation. The size is measured by laser diffusion. The determination of the rifampicin is carried out by high performance liquid chromatography coupled to a spectrophotometer. The mobile phase is composed of a mixture of methanol/0.05 M ammonium acetate (65:35). the pH is adjusted to 7.3, the flow rate is fixed at 1 ml/min and the absorption is read at 254 nm. The content of rifampicin which is not bound to the nanoparticles is measured in the supernatant obtained after ultracentrifugation of the nanoparticle suspension (80000 g. 1 h at 4° C.). The amount of rifampicin bound to the nanoparticles corresponds to the fraction present in the plug, which is dissolved in THF before proceeding with the direct rifampicin determination.
- The following results are obtained:
- size of the nanoparticles containing rifampicin: 266±63 nm before lyophilisation and 282±54 nm after lyophilisation;
- percentage binding of rifampicin : 8.5±0.5% before and after lyophilisation.
- The experiment is carried out in the same way as in Example 12, but the active principle being hydrosoluble, it is incorporated in the polymerisation medium at a concentration of 0.5 mg/ml before addition of the organic phase. The size of the nanoparticles containing colistin measured by laser diffusion is 282±65 nm after evaporation and 283±26 nm after conservation at +4° C. for 4 days. Determined according to the gelose diffusion technique (S. P. Gotoff et al., Antimicrob. Agents Chemother, 1962, 107-113), colistin is found at the concentration of 15 μg/ml in the supernatant obtained after ultracentrifugation of the nanoparticle suspension (80000 g, 1 hour at 4° C.): the fraction which is not bound to the nanoparticles is then evaluated at 3% of the total amount of colistin added.
- Preparation of nanoparticles containing azidothymidine (AZT) (Sigma Aldrich Chimie, France).
- 240 mg of 1-ethoxycarbonyl-1-ethoxycarbonylmethyleneoxycarbonyl-ethene monomer (Laboratoires UPSA/CARPIBEM. France), already desorbed of SO2 for 3 hours under 25 mbars, are dissolved in 2.5 ml acetone. With the aid of a propipette, this solution is then gradually added and with constant stirring to 22.5 ml of aqueous medium buffered at pH 8.0 with the aid of a phosphate buffer (Na2HPO4/KH2PO4 0.066 M) and containing 225 mg of dextran 70 (1% w/v), as well as the hydrosoluble active principle at a concentration of 0.53 mg/ml. After 18 hours' polymerisation at 20° C., 22.5 ml of demineralised water containing 5% of D-glucose are added with stirring to the nanoparticle suspension, the mixture is then submitted to an evaporation in vacuo with the aid of a Rotavapor (20° C., 25 mbars) so as to remove the acetone and to reduce the volume of the aqueous suspension to 39.0 ml. The preparation is then lyophilised; freezing takes place at −30° C. and sublimation at +20° C. for 36 hours at a pressure of 0.05 mbar.
- The size of the nanoparticles containing AZT measured by laser diffusion is 255±63 nm before lyophilisation. The content of AZT in the supernatant after centrifugation of the nanoparticle suspension (12000 rpm, 1 hour at 4° C.) is determined by UV spectrophotometry at 266 nm. A concentration of 98 μg/ml is obtained: the fraction which is not bound to the nanoparticles is therefore evaluated to be 31.9% of the total amount of AZT added. The fraction of AZT bound to the nanoparticles is therefore 68.1%.
- The encapsulation of creatine phosphate is carried out according to the technique of Example 14. The size of the nanoparticles containing creatine phosphate measured by laser diffusion is 275±260 nm before lyophilisation. The determination of the creatine phosphate is carried out by high performance liquid chromatography coupled to a spectrophotometer. The mobile phase is composed of a phosphate buffer (KH2PO4. 0.05 M) adjusted to pH 3.3. The flow rate is fixed at 2 ml/min and the absorption is read at 200 nm.
- The content of creatine phosphate which is not bound to the nanoparticles is measured in the supernatant obtained after centrifugation of the nanoparticle suspension (12000 rpm, 1 hour at 4° C.). The creatine phosphate is found at a concentration of 463 μg/ml in the supernatant: the fraction which is not bound to the nanoparticles is therefore evaluated at 81% of the total amount of creatine phosphate added. The fraction of creatine phosphate bound to the nanoparticles is therefore 19%.
- The encapsulation of 5-FU (Sigma Aldrich Chimie, France) is carried out according to the technique of Example 14. The size of the nanoparticles containing the 5-FU measured by laser diffusion is 516±88 nm before lyophilisation. Determined by UV spectrophotometry at 266 nm, the 5-EU is found at a concentration of 70 μg/ml in the supernatant obtained after centrifugation of the nanoparticle suspension (12 000 rpm, 1 hour at 4° C.): the fraction which is not bound to the nanoparticles is therefore evaluated at 23.3% of the total amount of 5-FU added. The fraction of 5-FU bound to the nanoparticles is therefore 76.7%.
Claims (23)
1. A method for the preparation of nanoparticles formed from a random polymer of at least one compound of formula (I)
group;
R1 and R2, identical or different, represent a linear or branched C1-C6 alkyl group;
n=1, 2, 3, 4 or 5;
characterised in that the monomer(s) is (are), before the polymerisation, dissolved in a water-miscible aprotic organic solvent forming, with the polymerisation medium, a non-solvent mixture of the polymer formed.
2. The method according to for the preparation of nanoparticles formed from a polymer of a compound of formula (I)
claim 1
group;
R1 and R2, identical or different, represents a linear or branched C1-C6 alkyl group;
—n=1, 2, 3, 4 or 5,
characterised in that before the polymerisation, the monomer is dissolved in a water-miscible aprotic organic solvent forming, with the polymerisation medium, a non-solvent mixture of the polymer formed.
3. The method according to one of claims 1 or 2, for the preparation of nanoparticles having a diameter of less than 500 nm. preferably between 100 and 500 nm, and an average molecular mass (Mw) between about 1000 and 100000, notably between about 1000 and 80000, in particular between about 2000 and 80000, preferably between about 8000 and 80000.
4. The method according to any one of to , characterised in that it comprises the steps consisting in:
claims 1
3
preparing a solution of at least one compound of formula (I) in a water-miscible aprotic organic solvent,
adding, with stirring, to this organic phase, an aqueous polymerisation medium at a pH between 4.5 and 10,
recovering the nanoparticles thus obtained after homogenisation of the mixture and evaporating the organic solvent in vacuo.
5. The method according to any one of to , characterised in that it comprises the steps consisting in:
claims 1
3
preparing a solution of at least one compound of formula (I) in a water-miscible aprotic organic solvent,
adding, with stirring, to this organic phase, an aqueous polymerisation medium at a pH between 4.5 and 10,
recovering the nanoparticles thus obtained after homogenisation of the mixture and evaporating the organic solvent in vacuo.
6. The method according to any one of to , characterised in that the aprotic organic solvent is selected from acetone, acetonitrile, dioxane and tetrahydrofuran.
claims 1
5
7. The method according to any one of to , characterised in that the concentration of compound(s) of formula (I) in the organic solvent is of the order of 30 mg/ml to 150 mg/ml.
claims 1
6
8. The method according to any one of to , characterised in that the molarity of the polymerisation medium is of the order of {fraction (1/30)}M to ⅓M.
claims 1
7
9. The method according to any one of to , characterised in that the polymerisation medium contains one or more surfactants or colloid protectors.
claims 1
8
10. The method according to , characterised in that the surfactants are non-ionic surfactants selected from copolymers of polyoxyethylene and polyoxypropylene, poloxamers and polysorbates.
claim 9
11. The method according to or , characterised in that the colloid protector agents are selected from dextrans, hydrosoluble cellulose derivatives, polyethylene glycols and poly(vinyl alcohol).
claim 9
10
12. The method according to any one of to , characterised in that the organic phase or the polymerisation medium contains one or more biologically active molecules.
claims 1
11
16. Nanoparticles formed from a random polymer of at least one methylidene malonate compound of formula (I)
group;
R1 and R2, identical or different, represents a linear or branched C1-C6 alkyl group;
n=1, 2, 3, 4 or 5,
having a diameter of less than 500 nm, preferably between 100 and 500 nm and an average molecular mass (Mw) between about 1000 and 100000, notably between 1000 and 80000, in particular between about 2 000 and 80 000, preferably between about 8000 and 80000, obtainable by the method according to any one of to .
claims 1
15
group;
R1 and R2, identical or different, represents a linear or branched C1-C6 alkyl group;
n=1, 2, 3, 4 or 5,
having a diameter of less than 500 nm. preferably between 100 and 500 nm and an average molecular mass (Mw) between about 1000 and 80000, in particular between about 2 000 and 80 000, preferably between about 8000 and 80000, obtainable by the method according to any one of to .
claims 1
15
group;
R1 and R2, identical or different, represents a linear or branched C1-C6 alkyl group;
n=1, 3, 4 or 5,
having a diameter of less than 500 nm, preferably between 100 and 500 nm and an average molecular mass (Mw) between about 8000 and 100000, preferably between about 8000 and 80000.
group;
R1 and R2, identical or different, represents a linear or branched C1-C6 alkyl group;
n=1, 2, 3, 4 or 5,
having a diameter of less than 500 nm, preferably between 100 and 500 nm and an average molecular mass (Mw) between about 8000 and 80000.
22. The nanoparticles according to any one of to , characterised in that they comprise one or more biologically active molecules.
claims 16
21
23. Pharmaceutical composition containing nanoparticles according to as active principle in association with a pharmaceutically acceptable vehicle.
claim 22
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/770,303 US6420468B2 (en) | 1996-10-25 | 2001-01-29 | Methylidene malonate nanoparticles |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR96/13039 | 1996-10-25 | ||
FR9613039A FR2755136B1 (en) | 1996-10-25 | 1996-10-25 | PROCESS FOR THE PREPARATION OF METHYLIDENE MALONATE NANOPARTICLES, NANOPARTICLES CONTAINING ONE OR MORE BIOLOGICALLY ACTIVE MOLECULES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US09/284,455 US6211273B1 (en) | 1996-10-25 | 1997-10-24 | Method for preparing malonate methylidene nanoparticles, nanoparticles optionally containing one or several biologically active molecules |
US09/770,303 US6420468B2 (en) | 1996-10-25 | 2001-01-29 | Methylidene malonate nanoparticles |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/284,455 Division US6211273B1 (en) | 1996-10-25 | 1997-10-24 | Method for preparing malonate methylidene nanoparticles, nanoparticles optionally containing one or several biologically active molecules |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010006989A1 true US20010006989A1 (en) | 2001-07-05 |
US6420468B2 US6420468B2 (en) | 2002-07-16 |
Family
ID=9497032
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/284,455 Expired - Lifetime US6211273B1 (en) | 1996-10-25 | 1997-10-24 | Method for preparing malonate methylidene nanoparticles, nanoparticles optionally containing one or several biologically active molecules |
US09/770,303 Expired - Fee Related US6420468B2 (en) | 1996-10-25 | 2001-01-29 | Methylidene malonate nanoparticles |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/284,455 Expired - Lifetime US6211273B1 (en) | 1996-10-25 | 1997-10-24 | Method for preparing malonate methylidene nanoparticles, nanoparticles optionally containing one or several biologically active molecules |
Country Status (23)
Country | Link |
---|---|
US (2) | US6211273B1 (en) |
EP (1) | EP0934059B1 (en) |
JP (1) | JP2001504530A (en) |
KR (1) | KR20000052813A (en) |
CN (1) | CN1237903A (en) |
AR (1) | AR009127A1 (en) |
AT (1) | ATE245171T1 (en) |
AU (1) | AU736097B2 (en) |
BR (1) | BR9712372A (en) |
CA (1) | CA2269783C (en) |
CZ (1) | CZ144099A3 (en) |
DE (1) | DE69723571T2 (en) |
FR (1) | FR2755136B1 (en) |
HU (1) | HUP9904359A3 (en) |
IL (1) | IL129355A0 (en) |
NO (1) | NO991942L (en) |
NZ (1) | NZ335094A (en) |
PL (1) | PL332957A1 (en) |
RU (1) | RU2214421C2 (en) |
SK (1) | SK55599A3 (en) |
TW (1) | TW503109B (en) |
WO (1) | WO1998018455A1 (en) |
ZA (1) | ZA979550B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100457824B1 (en) * | 2001-08-10 | 2004-11-18 | 한국화학연구원 | Solvothermal preparation of nano-sized divalent metal oxide powder |
US20070259032A1 (en) * | 2006-05-01 | 2007-11-08 | Corinne Bright | Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury |
EP2123262A1 (en) * | 2008-05-20 | 2009-11-25 | Consorzio per il Centro di Biomedica Moleculare Scrl | Polyelectrolyte-encapsulated gold nanoparticles capable of crossing blood-brain barrier |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2774096B1 (en) * | 1998-01-29 | 2000-04-07 | Virsol | NOVEL SURFACTANT COPOLYMERS BASED ON METHYLIDENE MALONATE |
FR2778100B1 (en) | 1998-04-29 | 2001-05-04 | Virsol | NOVEL POLY (METHYLIDENE MALONATE) MICROSPHERES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR2789314B1 (en) * | 1999-02-09 | 2001-04-27 | Virsol | WOUND SUTURE MATERIAL BASED ON METHYLIDENE MALONATE |
WO2001077238A1 (en) * | 2000-04-12 | 2001-10-18 | Dainippon Ink And Chemicals, Inc. | Antifouling coating composition and novel resin |
JP4611561B2 (en) * | 2000-04-12 | 2011-01-12 | Dic株式会社 | Novel vinyl resin and method for producing the same |
FR2812551B1 (en) * | 2000-08-07 | 2003-03-28 | Virsol | PHARMACEUTICAL FORM COMPRISING A METHYLIDENE MALONATE-BASED SUPPORT MATERIAL AND A CELL REGULATING FACTOR |
AU2002211602A1 (en) * | 2000-10-11 | 2002-04-22 | Johns Hopkins University | Polymer controlled delivery of a therapeutic agent |
JP3961312B2 (en) | 2002-02-26 | 2007-08-22 | 株式会社デンソー | Control device for internal combustion engine |
US8993795B2 (en) | 2009-05-07 | 2015-03-31 | Optmed Inc | Methylidene malonate process |
US8106234B2 (en) * | 2009-05-07 | 2012-01-31 | OptMed, Inc | Methylidene malonate process |
JP2014503474A (en) | 2010-10-20 | 2014-02-13 | バイオフオーミツクス・インコーポレイテツド | Synthesis of methylene malonate using rapid recovery in the presence of energy transfer means |
US9828324B2 (en) | 2010-10-20 | 2017-11-28 | Sirrus, Inc. | Methylene beta-diketone monomers, methods for making methylene beta-diketone monomers, polymerizable compositions and products formed therefrom |
US9279022B1 (en) | 2014-09-08 | 2016-03-08 | Sirrus, Inc. | Solution polymers including one or more 1,1-disubstituted alkene compounds, solution polymerization methods, and polymer compositions |
US10414839B2 (en) | 2010-10-20 | 2019-09-17 | Sirrus, Inc. | Polymers including a methylene beta-ketoester and products formed therefrom |
US9249265B1 (en) | 2014-09-08 | 2016-02-02 | Sirrus, Inc. | Emulsion polymers including one or more 1,1-disubstituted alkene compounds, emulsion methods, and polymer compositions |
JP6267643B2 (en) | 2011-10-19 | 2018-01-24 | シラス・インコーポレイテッド | Polyfunctional monomer, method for producing polyfunctional monomer, polymerizable composition and product formed therefrom |
JP6553505B2 (en) | 2012-03-30 | 2019-07-31 | シラス・インコーポレイテッド | Composite and laminate articles and polymerization systems for making them |
JP6188252B2 (en) | 2012-03-30 | 2017-08-30 | シラス・インコーポレイテッド | Method for activating polymerizable composition, polymerization system and product formed thereby |
US9234107B2 (en) | 2012-03-30 | 2016-01-12 | Sirrus, Inc. | Ink coating formulations and polymerizable systems for producing the same |
US10047192B2 (en) | 2012-06-01 | 2018-08-14 | Sirrus, Inc. | Optical material and articles formed therefrom |
WO2014078689A1 (en) | 2012-11-16 | 2014-05-22 | Bioformix Inc. | Plastics bonding systems and methods |
WO2014085570A1 (en) | 2012-11-30 | 2014-06-05 | Bioformix, Inc. | Composite compositions for electronics applications |
EP2943462B1 (en) | 2013-01-11 | 2018-06-27 | Sirrus, Inc. | Method to obtain methylene malonate via bis(hydroxymethyl) malonate pathway |
US9416091B1 (en) | 2015-02-04 | 2016-08-16 | Sirrus, Inc. | Catalytic transesterification of ester compounds with groups reactive under transesterification conditions |
US9315597B2 (en) | 2014-09-08 | 2016-04-19 | Sirrus, Inc. | Compositions containing 1,1-disubstituted alkene compounds for preparing polymers having enhanced glass transition temperatures |
US10501400B2 (en) | 2015-02-04 | 2019-12-10 | Sirrus, Inc. | Heterogeneous catalytic transesterification of ester compounds with groups reactive under transesterification conditions |
US9334430B1 (en) | 2015-05-29 | 2016-05-10 | Sirrus, Inc. | Encapsulated polymerization initiators, polymerization systems and methods using the same |
US9217098B1 (en) | 2015-06-01 | 2015-12-22 | Sirrus, Inc. | Electroinitiated polymerization of compositions having a 1,1-disubstituted alkene compound |
CN107709378B (en) * | 2015-06-19 | 2019-06-11 | 赛鲁斯股份有限公司 | It is used to prepare the composition containing the disubstituted olefin(e) compound of 1,1- of the polymer of the glass transition temperature with enhancing |
US9518001B1 (en) | 2016-05-13 | 2016-12-13 | Sirrus, Inc. | High purity 1,1-dicarbonyl substituted-1-alkenes and methods for their preparation |
US9617377B1 (en) | 2016-06-03 | 2017-04-11 | Sirrus, Inc. | Polyester macromers containing 1,1-dicarbonyl-substituted 1 alkenes |
US9567475B1 (en) | 2016-06-03 | 2017-02-14 | Sirrus, Inc. | Coatings containing polyester macromers containing 1,1-dicarbonyl-substituted 1 alkenes |
US10428177B2 (en) | 2016-06-03 | 2019-10-01 | Sirrus, Inc. | Water absorbing or water soluble polymers, intermediate compounds, and methods thereof |
US10196481B2 (en) | 2016-06-03 | 2019-02-05 | Sirrus, Inc. | Polymer and other compounds functionalized with terminal 1,1-disubstituted alkene monomer(s) and methods thereof |
KR102571880B1 (en) | 2017-06-02 | 2023-08-28 | 아르끄마 프랑스 | Curable Compositions and Uses Thereof |
WO2020123579A1 (en) * | 2018-12-11 | 2020-06-18 | Sirrus, Inc. | Polymerization of 1,1-dicarbonyl 1-alkenes |
JP2022541292A (en) | 2019-07-19 | 2022-09-22 | アルケマ フランス | Useful curable compositions for obtaining non-sensitizing cured products |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2965725D1 (en) * | 1978-07-19 | 1983-07-28 | Patrick Couvreur | Biodegradable nanoparticles, pharmaceutical compositions containing them and process for their preparation |
FR2611705B1 (en) * | 1987-03-05 | 1989-07-13 | Union Pharma Scient Appl | PROCESS FOR THE PREPARATION OF MONESTERS OR DIESTERS OF ENDOETHANO-9, 10 DIHYDRO-9, 10 ANTHRACENE BICARBOXYLIC ACID-11, 11, NOVEL MONESTERS OR DIESTERS THUS PREPARED AND THE USE THEREOF FOR THE PREPARATION OF ASYMENEMRICAL SYMMETRICS |
FR2722411B1 (en) * | 1994-07-18 | 1996-10-04 | Union Pharma Scient Appl | IMMUNONANOPARTICLES COATED WITH ANTI-BETA2 MICROGLOBULIN MONOCLONAL ANTIBODIES AND THEIR USE FOR PROPHYLAXIS AND / OR THE TREATMENT OF PATHOLOGIES DUE TO HIV VIRUS INFECTION |
-
1996
- 1996-10-25 FR FR9613039A patent/FR2755136B1/en not_active Expired - Lifetime
-
1997
- 1997-10-24 BR BR9712372-2A patent/BR9712372A/en not_active IP Right Cessation
- 1997-10-24 JP JP52010798A patent/JP2001504530A/en not_active Ceased
- 1997-10-24 PL PL97332957A patent/PL332957A1/en unknown
- 1997-10-24 CZ CZ991440A patent/CZ144099A3/en unknown
- 1997-10-24 DE DE69723571T patent/DE69723571T2/en not_active Expired - Fee Related
- 1997-10-24 AR ARP970104915A patent/AR009127A1/en unknown
- 1997-10-24 RU RU99110736/04A patent/RU2214421C2/en not_active IP Right Cessation
- 1997-10-24 HU HU9904359A patent/HUP9904359A3/en unknown
- 1997-10-24 CN CN97199824A patent/CN1237903A/en active Pending
- 1997-10-24 WO PCT/FR1997/001907 patent/WO1998018455A1/en not_active Application Discontinuation
- 1997-10-24 SK SK555-99A patent/SK55599A3/en unknown
- 1997-10-24 IL IL12935597A patent/IL129355A0/en unknown
- 1997-10-24 ZA ZA9709550A patent/ZA979550B/en unknown
- 1997-10-24 TW TW086115768A patent/TW503109B/en not_active IP Right Cessation
- 1997-10-24 KR KR1019990703636A patent/KR20000052813A/en not_active Application Discontinuation
- 1997-10-24 AT AT97912248T patent/ATE245171T1/en not_active IP Right Cessation
- 1997-10-24 CA CA002269783A patent/CA2269783C/en not_active Expired - Fee Related
- 1997-10-24 AU AU49509/97A patent/AU736097B2/en not_active Ceased
- 1997-10-24 EP EP97912248A patent/EP0934059B1/en not_active Expired - Lifetime
- 1997-10-24 US US09/284,455 patent/US6211273B1/en not_active Expired - Lifetime
-
1999
- 1999-04-23 NZ NZ335094A patent/NZ335094A/en unknown
- 1999-04-23 NO NO991942A patent/NO991942L/en not_active Application Discontinuation
-
2001
- 2001-01-29 US US09/770,303 patent/US6420468B2/en not_active Expired - Fee Related
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100457824B1 (en) * | 2001-08-10 | 2004-11-18 | 한국화학연구원 | Solvothermal preparation of nano-sized divalent metal oxide powder |
US20070259032A1 (en) * | 2006-05-01 | 2007-11-08 | Corinne Bright | Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury |
US8697120B2 (en) * | 2006-05-01 | 2014-04-15 | Johns Hopkins University | Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury |
US20140178465A1 (en) * | 2006-05-01 | 2014-06-26 | The Board Of Trustees Of The Leland Stanford Junior University | Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury |
US9737486B2 (en) * | 2006-05-01 | 2017-08-22 | The Board Of Trustees Of The Leland Stanford Junior University | Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury |
EP2123262A1 (en) * | 2008-05-20 | 2009-11-25 | Consorzio per il Centro di Biomedica Moleculare Scrl | Polyelectrolyte-encapsulated gold nanoparticles capable of crossing blood-brain barrier |
WO2009141329A1 (en) | 2008-05-20 | 2009-11-26 | Consorzio Per Il Centro Di Biomedicina Molecolare Scrl | Polyelectrolyte-encapsulated gold nanoparticles capable of crossing blood-brain barrier |
US20110111040A1 (en) * | 2008-05-20 | 2011-05-12 | Silke Krol | Polyelectrolyte-encapsulated gold nanoparticles capable of crossing blood-brain barrier |
Also Published As
Publication number | Publication date |
---|---|
TW503109B (en) | 2002-09-21 |
DE69723571T2 (en) | 2004-06-03 |
WO1998018455A1 (en) | 1998-05-07 |
CZ144099A3 (en) | 1999-09-15 |
CA2269783C (en) | 2005-01-11 |
AU4950997A (en) | 1998-05-22 |
EP0934059B1 (en) | 2003-07-16 |
NO991942D0 (en) | 1999-04-23 |
ATE245171T1 (en) | 2003-08-15 |
BR9712372A (en) | 2000-01-25 |
PL332957A1 (en) | 1999-10-25 |
SK55599A3 (en) | 2000-03-13 |
FR2755136A1 (en) | 1998-04-30 |
US6211273B1 (en) | 2001-04-03 |
FR2755136B1 (en) | 1999-01-22 |
ZA979550B (en) | 1998-05-12 |
HUP9904359A2 (en) | 2000-05-28 |
CN1237903A (en) | 1999-12-08 |
DE69723571D1 (en) | 2003-08-21 |
CA2269783A1 (en) | 1998-05-07 |
IL129355A0 (en) | 2000-02-17 |
US6420468B2 (en) | 2002-07-16 |
RU2214421C2 (en) | 2003-10-20 |
AU736097B2 (en) | 2001-07-26 |
NZ335094A (en) | 2001-05-25 |
JP2001504530A (en) | 2001-04-03 |
NO991942L (en) | 1999-06-23 |
HUP9904359A3 (en) | 2000-11-28 |
AR009127A1 (en) | 2000-03-08 |
KR20000052813A (en) | 2000-08-25 |
EP0934059A1 (en) | 1999-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6420468B2 (en) | Methylidene malonate nanoparticles | |
EP1372618B1 (en) | Colloidal suspension of nanoparticles based on an amphiphilic copolymer | |
Genta et al. | Different molecular weight chitosan microspheres: influence on drug loading and drug release | |
JP2002508020A (en) | Complex of polyethylene glycol and chitosan | |
EP1322411B1 (en) | Colloidal suspension of submicronic particles for carrying active principles and their mode of preparation | |
MX2007011212A (en) | Nanoparticles of chitosan and polyethyleneglycol as a system for the administration of biologically-active molecules. | |
WO1999055309A1 (en) | Novel poly(methylidene malonate) microspheres, preparation method and pharmaceutical compositions containing them | |
CN106832158B (en) | PH-responsive dynamic shell cross-linked polymer nano-particle and preparation method thereof | |
EP0591284A1 (en) | Carrier systems for drugs | |
CN105833287B (en) | Slow-release nano-drug carrier and preparation method and application thereof | |
CN108403662B (en) | Trihydroxymethyl aminomethane modified zein functional drug-loaded microsphere and preparation method thereof | |
Michailova et al. | Nanoparticles formed from PNIPAM-g-PEO copolymers in the presence of indomethacin | |
HUT72033A (en) | Nanoparticles containing an activ ingradient and a polyketal-succinicamide, and process for producing and using thereof | |
US20220339288A1 (en) | Macromonomers and bottle brush polymers for delivery of biological agents | |
KR100451019B1 (en) | Particulate carriers and pharmaceutical compositions containing the same | |
CN107011515B (en) | Triblock polymer and preparation method thereof | |
Puglisi et al. | Evaluation of polyalkylcyanoacrylate nanoparticles as a potential drug carrier: preparation, morphological characterization and loading capacity | |
MXPA99003827A (en) | Method for preparing malonate methylidene nanoparticles, nanoparticles optionally containing one or several biologically active molecules | |
CN114366816A (en) | Chitosan nanoparticles with excellent freeze-drying redispersibility, freeze-drying preparation, and preparation method and application thereof | |
CN112807443A (en) | Multiple synergistic antibacterial nano prodrug | |
CN112274655A (en) | Nano drug-loaded particle with poly citric acid as carrier and preparation method and application thereof | |
CN109833483A (en) | The preparation of Sorafenib Nano medication based on mini-chaperone | |
CN113501860B (en) | Assembled nano liquid metal particles and preparation method and application thereof | |
Tale | Amphiphilic and Random Copolymers: Self Assembly and Application in Drug Delivery Formulations | |
CN109464402B (en) | Multifunctional nano-medicine composition and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20060716 |